Psyence Group Inc. (PSYGF)

USD 0.02

(0.0%)

Market Cap (In USD)

2.8 Million

Revenue (In USD)

-

Net Income (In USD)

-69.44 Million

Avg. Volume

2815.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.0075-0.0611
PE
-
EPS
-
Beta Value
2.038
ISIN
CA74449Q1063
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Mr. Jody Aufrichtig
Employee Count
-
Website
https://www.psyence.com
Ipo Date
2022-05-31
Details
Psyence Group Inc., a life science biotechnology company, engages in the commercial psilocybin mushroom cultivation and production activities. Its natural psilocybin is used for the treatment of a range of mental health disorders and other medical conditions. The company is developing pharmaceutical preparations of psilocybin doses to help heal psychological trauma and diagnosable disorders, including anxiety, depression, post-traumatic stress disorder, and grief and bereavement. It also focuses on the development, distribution, and sale of over-the-counter non psilocybin containing functional mushroom nutraceutical products under the GOODMIND brand. Psyence Group Inc. was founded in 2019 and is based in Toronto, Canada.